Alpha 2.0
Login Register
» Articles » PMID: 27943467

Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies

Overview
Journal Haemophilia
Specialty Hematology
Date 2016 Dec 13
PMID 27943467
Citations 7
Authors
D V Quon
R Klamroth
R Kulkarni
A D Shapiro
R I Baker
G Castaman
B A Kerlin
E Tsao
G Allen
Affiliations
Soon will be listed here.
Citing Articles

Efmoroctocog Alfa: A Review in Haemophilia A.

Frampton J Drugs. 2021; 81(17):2035-2046.

PMID: 34743314 PMC: 8636404. DOI: 10.1007/s40265-021-01615-w.

Recombinant factor VIII Fc for the treatment of haemophilia A.

Hermans C, Mancuso M, Nolan B, Pasi K Eur J Haematol. 2021; 106(6):745-761.

PMID: 33650192 PMC: 8252769. DOI: 10.1111/ejh.13610.

Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.

Shrestha A, Su J, Li N, Barnowski C, Jain N, Everson K Res Pract Thromb Haemost. 2021; 5(1):94-103.

PMID: 33537533 PMC: 7845067. DOI: 10.1002/rth2.12437.

Achieving the unimaginable: Health equity in haemophilia.

Skinner M, Nugent D, Wilton P, OMahony B, Dolan G, OHara J Haemophilia. 2019; 26(1):17-24.

PMID: 31724316 PMC: 7891319. DOI: 10.1111/hae.13862.

Emerging therapies for hemophilia: controversies and unanswered questions.

Arruda V, Doshi B, Samelson-Jones B F1000Res. 2018; 7.

PMID: 29770199 PMC: 5931262. DOI: 10.12688/f1000research.12491.1.